<ul>
<li>分析师表示这两家中型生物科技公司具有两倍的潜力</li>
</ul>
<p>Ultragenyx Pharmaceutical Inc.（NASDAQ:RARE - 免费报告）- HC Wainwright 的研究分析师在 5 月 11 日星期一发布的研究报告中下调了 Ultragenyx Pharmaceutical 的 2027 年第一季度收益预期。HC Wainwright 的分析师 R. Selvaraju 现在预计这家生物制药公司本季度每股收益为 0.27 美元，低于之前的 0.28 美元。HC Wainwright 目前对该股票给予 “买入” 评级，目标价为 50.00 美元。市场普遍预计 Ultragenyx Pharmaceutical 当前全年的每股收益为（4.61 美元）。HC Wainwright 还对 Ultragenyx Pharmaceutical 的 2027 年第二季度收益预期为每股 1.18 美元，第三季度收益为每股 1.54 美元，第四季度收益为每股 2.63 美元，以及 2027 财年的收益为每股 5.61 美元。</p>
<p>RARE 还受到其他几份报告的关注。Weiss Ratings 在周五的报告中将 Ultragenyx Pharmaceutical 的股票评级从 “卖出（e+）” 上调至 “卖出（d-）”。Wedbush 在 5 月 6 日星期三的研究报告中将 Ultragenyx Pharmaceutical 的目标价从 27.00 美元下调至 26.00 美元，并对该公司给予 “中性” 评级。Wall Street Zen 在周一的研究报告中将 Ultragenyx Pharmaceutical 的股票评级从 “持有” 下调至 “强烈卖出”。Wells Fargo &amp; Company 在 5 月 6 日星期三的研究报告中将 Ultragenyx Pharmaceutical 的目标价从 45.00 美元上调至 47.00 美元，并给予该公司 “超配” 评级。最后，Barclays 在 4 月 29 日星期三的研究报告中将 Ultragenyx Pharmaceutical 的目标价从 44.00 美元下调至 43.00 美元，并对该公司给予 “超配” 评级。一位研究分析师对该股票给予 “强烈买入” 评级，十四位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat，Ultragenyx Pharmaceutical 目前的平均评级为 “适度买入”，共识目标价为 60.41 美元。</p>
<p><strong>获取我们关于 Ultragenyx Pharmaceutical 的最新研究报告</strong></p>
<h2>Ultragenyx Pharmaceutical 股票表现</h2>
<p>NASDAQ RARE 在周二开盘价为 26.30 美元。Ultragenyx Pharmaceutical 的年低为 18.29 美元，年高为 42.37 美元。该公司的 50 日简单移动平均线为 22.81 美元，200 日简单移动平均线为 26.68 美元。该公司的市值为 25.9 亿美元，市盈率为-4.30，贝塔值为 0.39。</p>
<p>Ultragenyx Pharmaceutical（NASDAQ:RARE - 获取免费报告）在 5 月 5 日星期二最后发布了其收益结果。这家生物制药公司报告本季度每股收益为（1.84 美元），低于市场共识预期的（1.49 美元）0.35 美元。该公司在本季度的收入为 1.36 亿美元，而市场共识预期为 1.5819 亿美元。Ultragenyx Pharmaceutical 的股本回报率为-1,024.42%，净利润率为-91.03%。Ultragenyx Pharmaceutical 本季度的收入同比下降了 2.2%。在去年同期，该公司每股收益为（1.57 美元）。</p>
<h2>Ultragenyx Pharmaceutical 的机构交易</h2>
<p>最近，一些对冲基金和其他机构投资者对该公司的持仓进行了调整。Vanguard Group Inc.在第四季度将其在 Ultragenyx Pharmaceutical 的持股增加了 1.3%。Vanguard Group Inc.目前拥有 10,263,815 股该生物制药公司的股票，价值 236,068,000 美元，此前在上个季度购买了 131,087 股。State Street Corp 在第四季度将其在 Ultragenyx Pharmaceutical 的持股增加了 16.5%。State Street Corp 目前拥有 4,303,046 股该生物制药公司的股票，价值 98,970,000 美元，此前在上个季度购买了 610,559 股。Wellington Management Group LLP 在第四季度将其在 Ultragenyx Pharmaceutical 的持股增加了 26.6%。Wellington Management Group LLP 目前拥有 2,461,910 股该生物制药公司的股票，价值 56,624,000 美元，此前在上个季度购买了 516,781 股。Assenagon Asset Management S.A.在第一季度将其在 Ultragenyx Pharmaceutical 的持股增加了 1,030.4%。Assenagon Asset Management S.A.目前拥有 2,257,671 股该生物制药公司的股票，价值 47,298,000 美元，此前在上个季度购买了 2,057,951 股。最后，Jacobs Levy Equity Management Inc.在第三季度将其在 Ultragenyx Pharmaceutical 的持股增加了 614.1%。Jacobs Levy Equity Management Inc.目前拥有 2,167,729 股该生物制药公司的股票，价值 65,205,000 美元，此前在上个季度购买了 1,864,164 股。97.67% 的股票目前由机构投资者持有。</p>
<h2>内部活动</h2>
<p>在其他新闻中，执行副总裁 Karah Herdman Parschauer 于 3 月 2 日星期一出售了 8,135 股公司的股票。股票以平均价格 22.80 美元出售，总价值为 185,478.00 美元。出售完成后，这位执行副总裁直接持有 76,346 股公司的股票，估值约为 1,740,688.80 美元。这代表其持股比例下降了 9.63%。此次出售在向 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，首席财务官 Howard Horn 于 3 月 2 日星期一出售了 8,409 股公司的股票。股票以平均价格 22.70 美元出售，总交易额为 190,884.30 美元。出售完成后，首席财务官持有 86,669 股公司的股票，估值为 1,967,386.30 美元。此次交易使其持股比例下降了 8.84%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月内，内部人士共出售了 111,522 股公司股票，价值 2,543,214 美元。内部人士持有公司 5.20% 的股票。</p>
<h2>Ultragenyx 制药公司简介</h2>
<p>(获取免费报告)</p>
<p>Ultragenyx Pharmaceutical Inc 是一家生物制药公司，专注于开发和商业化针对罕见和超罕见遗传疾病的疗法。自 2010 年成立并在加利福尼亚州诺瓦托设立总部以来，该公司在蛋白质替代疗法、小分子和基因治疗方法方面积累了专业知识，以满足高度未满足的医疗需求。Ultragenyx 采用精准医疗模型，利用内部研究和战略合作，推动其产品管线从发现到监管批准的进展。</p>
<p>该公司的商业产品组合包括用于 X 连锁低磷血症的 Crysvita（burosumab-tmyl）、用于粘多糖贮积症 VII 的 Mepsevii（vestronidase alfa-vjbk）和用于长链脂肪酸氧化障碍的 Dojolvi（triheptanoin）。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们认为比 Ultragenyx Pharmaceutical 更好的股票</li>
<li>TMC 在海底打造新的电动车供应链</li>
<li>五月卖出，远离市场——从这三只股票开始</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ultragenyx 制药吗？</h2>
<p>在考虑 Ultragenyx 制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ultragenyx 制药并不在名单上。</p>
<p>虽然 Ultragenyx 制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ultragenyx制药

IBBQ

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>HC Wainwright 已将 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) 2027 年第一季度的每股收益预估从 $0.28 下调至 $0.27。该公司维持 “买入” 评级，目标价为 $50.00。市场对该公司全年收益的共识预估为每股 ($4.61)。其他分析师的评级各不相同，其中一位为强力买入，十四位为买入，两位为持有，一位为卖出。Ultragenyx 的股票开盘价为 $26.30，市值为 $25.9 亿，市盈率为 -4.30。该公司报告上个季度每股收益为 ($1.84)，未能达到预期</p>

<ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师表示这两家中型生物科技公司具有两倍的潜力</li>
</ul>
</div><p>Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at HC Wainwright dropped their Q1 2027 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of $0.27 per share for the quarter, down from their previous estimate of $0.28. HC Wainwright currently has a &#34;Buy&#34; rating and a $50.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($4.61) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q2 2027 earnings at $1.18 EPS, Q3 2027 earnings at $1.54 EPS, Q4 2027 earnings at $2.63 EPS and FY2027 earnings at $5.61 EPS.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical Inc.（NASDAQ:RARE - 免费报告）- HC Wainwright 的研究分析师在 5 月 11 日星期一发布的研究报告中下调了 Ultragenyx Pharmaceutical 的 2027 年第一季度收益预期。HC Wainwright 的分析师 R. Selvaraju 现在预计这家生物制药公司本季度每股收益为 0.27 美元，低于之前的 0.28 美元。HC Wainwright 目前对该股票给予 “买入” 评级，目标价为 50.00 美元。市场普遍预计 Ultragenyx Pharmaceutical 当前全年的每股收益为（4.61 美元）。HC Wainwright 还对 Ultragenyx Pharmaceutical 的 2027 年第二季度收益预期为每股 1.18 美元，第三季度收益为每股 1.54 美元，第四季度收益为每股 2.63 美元，以及 2027 财年的收益为每股 5.61 美元。</p>
</div><p>RARE has been the subject of several other reports. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a report on Friday. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a &#34;neutral&#34; rating for the company in a research note on Wednesday, May 6th. Wall Street Zen lowered shares of Ultragenyx Pharmaceutical from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday. Wells Fargo &amp; Company boosted their target price on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, May 6th. Finally, Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $60.41.</p>
<div class="lb-trans"><p>RARE 还受到其他几份报告的关注。Weiss Ratings 在周五的报告中将 Ultragenyx Pharmaceutical 的股票评级从 “卖出（e+）” 上调至 “卖出（d-）”。Wedbush 在 5 月 6 日星期三的研究报告中将 Ultragenyx Pharmaceutical 的目标价从 27.00 美元下调至 26.00 美元，并对该公司给予 “中性” 评级。Wall Street Zen 在周一的研究报告中将 Ultragenyx Pharmaceutical 的股票评级从 “持有” 下调至 “强烈卖出”。Wells Fargo &amp; Company 在 5 月 6 日星期三的研究报告中将 Ultragenyx Pharmaceutical 的目标价从 45.00 美元上调至 47.00 美元，并给予该公司 “超配” 评级。最后，Barclays 在 4 月 29 日星期三的研究报告中将 Ultragenyx Pharmaceutical 的目标价从 44.00 美元下调至 43.00 美元，并对该公司给予 “超配” 评级。一位研究分析师对该股票给予 “强烈买入” 评级，十四位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat，Ultragenyx Pharmaceutical 目前的平均评级为 “适度买入”，共识目标价为 60.41 美元。</p>
</div><p><strong>Get Our Latest Research Report on Ultragenyx Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Ultragenyx Pharmaceutical 的最新研究报告</strong></p>
</div><h2>Ultragenyx Pharmaceutical Stock Performance</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 股票表现</h2>
</div><p>NASDAQ RARE opened at $26.30 on Tuesday. Ultragenyx Pharmaceutical has a one year low of $18.29 and a one year high of $42.37. The company has a 50-day simple moving average of $22.81 and a 200-day simple moving average of $26.68. The firm has a market capitalization of $2.59 billion, a PE ratio of -4.30 and a beta of 0.39.</p>
<div class="lb-trans"><p>NASDAQ RARE 在周二开盘价为 26.30 美元。Ultragenyx Pharmaceutical 的年低为 18.29 美元，年高为 42.37 美元。该公司的 50 日简单移动平均线为 22.81 美元，200 日简单移动平均线为 26.68 美元。该公司的市值为 25.9 亿美元，市盈率为-4.30，贝塔值为 0.39。</p>
</div><p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.Ultragenyx Pharmaceutical's revenue for the quarter was down 2.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.57) EPS.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical（NASDAQ:RARE - 获取免费报告）在 5 月 5 日星期二最后发布了其收益结果。这家生物制药公司报告本季度每股收益为（1.84 美元），低于市场共识预期的（1.49 美元）0.35 美元。该公司在本季度的收入为 1.36 亿美元，而市场共识预期为 1.5819 亿美元。Ultragenyx Pharmaceutical 的股本回报率为-1,024.42%，净利润率为-91.03%。Ultragenyx Pharmaceutical 本季度的收入同比下降了 2.2%。在去年同期，该公司每股收益为（1.57 美元）。</p>
</div><h2>Institutional Trading of Ultragenyx Pharmaceutical</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company's stock worth $236,068,000 after purchasing an additional 131,087 shares in the last quarter. State Street Corp raised its holdings in shares of Ultragenyx Pharmaceutical by 16.5% in the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company's stock worth $98,970,000 after purchasing an additional 610,559 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Ultragenyx Pharmaceutical by 26.6% in the 4th quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company's stock worth $56,624,000 after purchasing an additional 516,781 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company's stock worth $47,298,000 after purchasing an additional 2,057,951 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock worth $65,205,000 after purchasing an additional 1,864,164 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>最近，一些对冲基金和其他机构投资者对该公司的持仓进行了调整。Vanguard Group Inc.在第四季度将其在 Ultragenyx Pharmaceutical 的持股增加了 1.3%。Vanguard Group Inc.目前拥有 10,263,815 股该生物制药公司的股票，价值 236,068,000 美元，此前在上个季度购买了 131,087 股。State Street Corp 在第四季度将其在 Ultragenyx Pharmaceutical 的持股增加了 16.5%。State Street Corp 目前拥有 4,303,046 股该生物制药公司的股票，价值 98,970,000 美元，此前在上个季度购买了 610,559 股。Wellington Management Group LLP 在第四季度将其在 Ultragenyx Pharmaceutical 的持股增加了 26.6%。Wellington Management Group LLP 目前拥有 2,461,910 股该生物制药公司的股票，价值 56,624,000 美元，此前在上个季度购买了 516,781 股。Assenagon Asset Management S.A.在第一季度将其在 Ultragenyx Pharmaceutical 的持股增加了 1,030.4%。Assenagon Asset Management S.A.目前拥有 2,257,671 股该生物制药公司的股票，价值 47,298,000 美元，此前在上个季度购买了 2,057,951 股。最后，Jacobs Levy Equity Management Inc.在第三季度将其在 Ultragenyx Pharmaceutical 的持股增加了 614.1%。Jacobs Levy Equity Management Inc.目前拥有 2,167,729 股该生物制药公司的股票，价值 65,205,000 美元，此前在上个季度购买了 1,864,164 股。97.67% 的股票目前由机构投资者持有。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the sale, the executive vice president directly owned 76,346 shares of the company's stock, valued at approximately $1,740,688.80. This represents a 9.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 8,409 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the sale, the chief financial officer owned 86,669 shares in the company, valued at $1,967,386.30. The trade was a 8.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 111,522 shares of company stock worth $2,543,214 over the last three months. Insiders own 5.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Karah Herdman Parschauer 于 3 月 2 日星期一出售了 8,135 股公司的股票。股票以平均价格 22.80 美元出售，总价值为 185,478.00 美元。出售完成后，这位执行副总裁直接持有 76,346 股公司的股票，估值约为 1,740,688.80 美元。这代表其持股比例下降了 9.63%。此次出售在向 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，首席财务官 Howard Horn 于 3 月 2 日星期一出售了 8,409 股公司的股票。股票以平均价格 22.70 美元出售，总交易额为 190,884.30 美元。出售完成后，首席财务官持有 86,669 股公司的股票，估值为 1,967,386.30 美元。此次交易使其持股比例下降了 8.84%。有关此次出售的更多细节可在官方 SEC 披露中找到。过去三个月内，内部人士共出售了 111,522 股公司股票，价值 2,543,214 美元。内部人士持有公司 5.20% 的股票。</p>
</div><h2>Ultragenyx Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>Ultragenyx 制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical Inc 是一家生物制药公司，专注于开发和商业化针对罕见和超罕见遗传疾病的疗法。自 2010 年成立并在加利福尼亚州诺瓦托设立总部以来，该公司在蛋白质替代疗法、小分子和基因治疗方法方面积累了专业知识，以满足高度未满足的医疗需求。Ultragenyx 采用精准医疗模型，利用内部研究和战略合作，推动其产品管线从发现到监管批准的进展。</p>
</div><p>The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.</p>
<div class="lb-trans"><p>该公司的商业产品组合包括用于 X 连锁低磷血症的 Crysvita（burosumab-tmyl）、用于粘多糖贮积症 VII 的 Mepsevii（vestronidase alfa-vjbk）和用于长链脂肪酸氧化障碍的 Dojolvi（triheptanoin）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Ultragenyx Pharmaceutical</li>
<li>TMC Forges a New EV Supply Chain at the Bottom of the Sea</li>
<li>Sell in May and Go Away—Starting With These 3 Stocks</li>
<li>Before the Moon Base Gets Built, These 4 Companies Win</li>
<li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Ultragenyx Pharmaceutical 更好的股票</li>
<li>TMC 在海底打造新的电动车供应链</li>
<li>五月卖出，远离市场——从这三只股票开始</li>
<li>在月球基地建成之前，这四家公司获胜</li>
<li>工业回购：顶级住宅建筑供应商引领回购增加</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=RARE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ultragenyx 制药吗？</h2>
</div><p>Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ultragenyx 制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ultragenyx 制药并不在名单上。</p>
</div><p>While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ultragenyx 制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 的经纪商下调了 RARE 的盈利预期